Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)-Reference-Cited by-同舟云学术

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

Published:2018-11 Issue:11 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lupien Andréanne¹,Vocat Anthony¹,Foo Caroline Shi-Yan¹^ORCID,Blattes Emilyne²,Gillon Jean-Yves²,Makarov Vadim³,Cole Stewart T.¹

Affiliation:

1. Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

2. Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland

3. Department of Stresses of Microorganisms, A. N. Bach Institute of Biochemistry, Moscow, Russian Federation

Abstract

The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis . Intensive efforts have been made to develop new antibiotics or to repurpose old drugs, and several of these are currently being evaluated in clinical trials for their antitubercular activity.

Funder

EC | FP7 | FP7 Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00840-18

Reference34 articles.

1. WHO. 2017. Global tuberculosis report. WHO, Geneva, Switzerland.

2. Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis

3. Repurposing clinically approved cephalosporins for tuberculosis therapy